CA-ROOTSTOCK-SOFTWARE
30.6.2020 07:02:07 CEST | Business Wire | Press release
Some partnerships are strengthened through difficult times. Rootstock Software and Mobidiag Ltd . found themselves in just this situation. Collaborating since 2018, the two companies have now been working toward respective missions around the COVID-19 pandemic. Mobidiag is a manufacturer of molecular diagnostic solutions for the detection of infectious diseases. Rootstock is a leading provider of Cloud ERP on the Salesforce Platform .
When the pandemic hit, Mobidiag quickly mobilized to develop and launch tests to detect COVID-19 infections. In April 2020, it was granted emergency use authorization for its COVID-19 diagnostic tests in Finland, Sweden and France. Now, in June, it has received CE-IVD markings for its two tests that enable rapid and reliable detection of COVID-19 infections:
- Novodiag™ COVID-19 for single, on-demand tests.
- Amplidiag™ COVID-19 for batch volume tests at large laboratories.
These two tests are complemented by an antibody test, Anti-SARS-CoV-2 Rapid Test , which Mobidiag distributes from its venture partner in China, Autobio Diagnostics.
All together these tests mean Mobidiag offers a comprehensive diagnostic solution for novel coronavirus infections for hospital and lab-based settings, and it comes at an opportune time, as the demand for COVID-19 diagnostic devices and tests is high around the world.
“Since April 2018, we have used Rootstock ERP along with Salesforce Sales Cloud and Service Cloud,” said Harri Vaihinen, Senior Business Solution Specialist at Mobidiag . “We worked with Rootstock to enable greater integration and automation of our key processes across sales, inventory and service for greater efficiency, synchronization and a full view of data across these departments. Since we had this ERP and integrated processes in place, we were able to use these tools to support our rapidly increasing sales, including COVID-19 tests.”
“During the pandemic, Rootstock’s mission has been to support manufacturers, distributors and supply chain organizations in continuing to deliver vital products around the world,” said Pat Garrehy , CEO of Rootstock Software . “It’s impressive to have seen the strides Mobidiag has made to get their COVID-19 tests to market in such an accelerated timeframe. The world needs COVID-19 testing, and it’s gratifying to play even a small role in supporting Mobidiag in their objective to detect COVID-19 infections and slow the spread of the virus.”
Salesforce, Sales Cloud and others are among the trademarks of salesforce.com, inc.
About Mobidiag
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag™ and Novodiag™ solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
About Rootstock
Rootstock Software is a worldwide provider of cloud ERP designed for manufacturing, distribution, and supply chain organizations. Rootstock Cloud ERP is a flexible, modern, and digitally connected system that transforms companies to deliver a more personalized customer experience, efficiently scale operations, and out-service the competition.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005024/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom